Astellas Pharma (OTCMKTS:ALPMY) Shares Gap Up – Still a Buy?

Astellas Pharma Inc. (OTCMKTS:ALPMY) gapped up before the market opened on Thursday. The stock had previously closed at $14.47, but opened at $15.16. Astellas Pharma shares last traded at $14.45, with a volume of 36,657 shares.

Analysts Set New Price Targets

Separately, Zacks Research lowered shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy”.

Astellas Pharma Stock Performance

The company has a quick ratio of 0.93, a current ratio of 1.20 and a debt-to-equity ratio of 0.16. The firm has a fifty day moving average of $14.64 and a 200-day moving average of $14.52. The stock has a market capitalization of $26.18 billion, a price-to-earnings ratio of 11.01 and a beta of 0.08.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Japan-based pharmaceutical company that researches, develops, manufactures and commercializes prescription medicines for patients worldwide. Its portfolio focuses on areas of significant unmet medical need, including oncology, immunology, urology, ophthalmology, neuroscience and medical conditions related to genetic regulation.

The company’s products include XTANDI (enzalutamide) for certain prostate cancers, XOSPATA (gilteritinib) for acute myeloid leukemia, PADCEV (enfortumab vedotin-ejfv) for certain urothelial cancers, and PROGRAF (tacrolimus), an immunosuppressant used primarily to help prevent organ rejection following transplantation.